Huahai Pharmaceuticals' New Drug Brief Application for FDA Provisional Approval
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Huahai Pharmaceuticals received theof the United States The FDA's notice(http://that theCompany's(http://http://
application fornew drug(http:// of the exofall saban spres filed with the FDA has been provisionally approved (temporary approval means that the FDA has completed all review requirements for generic drugs, but is a form of approval granted by theof the(http://or monopoly rights that have not expiredso far, Huahai Pharmaceuticals has invested about 14.7005 million yuan in research and development on the DevaShaban film projectAs thedrug(http://is still in the patent protection period, currently only the original researchproducts(http:// on the marketmarketHuahai Pharmaceuticals said that the infashaban tablets received provisional FDA approval, marking the product passed all the review requirements of the generic drugHowever, the product needs to expire and receive final FDA approval before it can be sold in the U.Smarketthe fda's provisional approval of the "Devasaban" marked a further advance in the company's business in the generic products sector and had a positive impact on the company's expansion into the U.Smarket
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
